Home › Acute Lymphoblastic Leukemia › NCT07071051

Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study

Who can join

Ages 2 to 22 · All sexes

Inclusion Criteria:

* Age 2-21.5 years
* Confirmed diagnosis of acute lymphoblastic leukemia/lymphoma
* Planned treatment with Cal-PEG
* Informed consent obtained from parents or guardians

Exclusion Criteria:

* Pre-existing coagulation disorders
* Known hypersensitivity to asparaginase products
* Liver failure
* Any acute or chronic disease that is known to affect coagulation testing (e.g. nephrotic syndrome)
* Currently pregnant
* Use of systemic blood thinner within 48 hours prior to study blood draw

About the study

This study evaluates the impact of calaspargase pegol (Cal-PEG) on the coagulation system in pediatric patients with acute lymphoblastic leukemia/lymphoma (ALL).

What is being tested

• Non-Interventional Study (other)

Sponsor: Mayo Clinic · Participants: 15 · Started: Jul 31, 2025

Contact the study team

• Clinical Trials Referral Office · Phone: 855-776-0015

Official record on ClinicalTrials.gov — NCT07071051

Locations in the U.S.

Conditions

• Acute Lymphoblastic Leukemia

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.